Bristol Myers SquibbRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Bristol Myers Squibb (BMY) reported revenue of $12.97B in Q2 2026, with Eliquis its largest revenue segment at 35%.
Bristol Myers SquibbBristol Myers Squibb sells Eliquis (with Pfizer), the Opdivo/Qvantig immuno-oncology franchise, and a Growth Portfolio that includes Reblozyl, Camzyos, Breyanzi, and Opdualag. The 1989 Bristol-Myers and Squibb merger created the current company.
Bristol Myers Squibb (BMY) is a Pharmaceuticals company. Bristol Myers Squibb sells Eliquis (with Pfizer), the Opdivo/Qvantig immuno-oncology franchise, and a Growth Portfolio that includes Reblozyl, Camzyos, Breyanzi, and Opdualag. The 1989 Bristol-Myers and Squibb merger created the current company. It was founded in 1989, is headquartered in Princeton, New Jersey and employs about 32,500 people.
As of 2026-Q2, Bristol Myers Squibb's revenue breaks down across Eliquis (35%), Opdivo (19%), Orencia (8%), Yervoy (6%). See the revenue-by-segment chart for the full mix.
Track Bristol Myers Squibb's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Bristol Myers Squibb in the Healthcare sector, alongside Johnson & Johnson (JNJ), Viatris (VTRS) and Zoetis (ZTS).
If you are researching Bristol Myers Squibb, also look at Johnson & Johnson (JNJ), Viatris (VTRS) and Zoetis (ZTS). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026